What Is New?
This 24-month study evaluated the efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia and elevated low-density lipoprotein cholesterol (LDL-C) levels despite maximum tolerated doses of LDL-C–lowering therapies with or without lipoprotein apheresis.There was no statistically significant difference in LDL-C reduction from baseline to day 150 between the placebo and the inclisiran group despite a reduction in PCSK9 (proprotein convertase subtilisin/kexin type 9) levels of 60% that was sustained throughout the study.